Clinical trials: Skin and Subcutaneous Tissue Bacterial Infections
Hidradenitis Suppurativa
Anakinra as a Treatment for Hydradenitis Suppurativa
This is an open-label, proof-of-concept research study to assess the effectiveness of anakinra in the treatment of patients with hidradenitis suppurativa (HS).
- Trial name
- NCT01516749
- Testing
- anakinra
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
INFECTIONS, Skin and Subcutaneous Tissue Bacterial Infections
Study of Accuracy of New Diagnostic Technology to Guide Rapid Antibiotic Treatment for Serious Infections
This research will test a new ultra-rapid technology (called ID/AST Accelerate system) that uses a digital microscope to identify bacteria based on their growth patterns.
- Conditions
- INFECTIONS, Skin and Subcutaneous Tissue Bacterial Infections, Healthcare-associated Infection, Infection Due to Resistant Bacteria
- Trial name
- NCT02796716
- Testing
- Testing on new technology called Accelerate ID/AST system
- Where
- United States
- Volunteers
- 2,102 people
- Sponsor
- Denver Health and Hospital Authority
Hidradenitis Suppurativa, Atopic Dermatitis
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort.
- Trial name
- NCT06524635
- Testing
- Lutikizumab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy
Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin…
- Trial name
- NCT05139602
- Testing
- Lutikizumab
- Where
- 54 sites in United States, Australia and 6 more
- Volunteers
- 210 people
- Sponsor
- AbbVie
Infection of Skin and/or Subcutaneous Tissue
Clinical Usefulness of Mic/Breakpoint Ratio and Penetration in Tissues. A Prospective Study of Clinical Validation
The general objective of the study is to assess whether the implementation of the antibiotic essay with the Breakpoint/MIC ratio and data on penetration of the antibiotic in the site of infection may improve the outcome of…
- Trial name
- NCT01551719
- Testing
- Implemented procedure
- Where
- 2 sites in Italy
- Sponsor
- Federico II University
Hidradenitis Suppurativa
Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
This study is to investigate the efficacy of siplizumab in the treatment of Hidradenitis Suppurativa.
- Trial name
- NCT06326476
- Testing
- Siplizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Alabama at Birmingham
Hidradenitis Suppurativa
Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab.
Hidradenitis Suppurativa (HS) is a severe, chronic debilitating disease with a variable and incomplete response to current treatments.
- Trial name
- NCT04084665
- Testing
- Guselkumab
- Where
- United States
- Sponsor
- Rockefeller University